<SEC-DOCUMENT>0001213900-19-020155.txt : 20191011
<SEC-HEADER>0001213900-19-020155.hdr.sgml : 20191011
<ACCEPTANCE-DATETIME>20191010181916
ACCESSION NUMBER:		0001213900-19-020155
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191010
FILED AS OF DATE:		20191011
DATE AS OF CHANGE:		20191010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Therapix Biosciences Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		191146806

	BUSINESS ADDRESS:	
		STREET 1:		4 ARIEL SHARON STREET
		STREET 2:		HASHAHAR TOWER, 16TH FLOOR
		CITY:			GIV?ATAYIM
		STATE:			L3
		ZIP:			5320047
		BUSINESS PHONE:		972-3-6167055

	MAIL ADDRESS:	
		STREET 1:		4 ARIEL SHARON STREET
		STREET 2:		HASHAHAR TOWER, 16TH FLOOR
		CITY:			GIV?ATAYIM
		STATE:			L3
		ZIP:			5320047
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k101019_therapixbio.htm
<DESCRIPTION>CURRENT REPORT OF FOREIGN ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the month of:&nbsp;October 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission file number:&nbsp;001- 38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>THERAPIX BIOSCIENCES LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Translation of registrant&rsquo;s name into
English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>4 Ariel Sharon Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>HaShahar Tower, 16th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Givatayim 5320047, Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Attached hereto and incorporated herein is
the Registrant&rsquo;s press release issued on&nbsp;<FONT STYLE="background-color: white">October 10, 2019,&nbsp;</FONT>titled
&ldquo;Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.&rdquo;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
press release  is incorporated by reference into the registration statements on&nbsp;Form F-3&nbsp;(File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018007936/ff32018_therapixbio.htm">333-225745</A>
and File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm">333-233417</A>)
and on&nbsp;Form&nbsp;S-8&nbsp;(File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A>)
of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this
report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35.8pt; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 4.4pt">&nbsp;</TD>
    <TD STYLE="width: 396.45pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>99.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f6k101019ex99-1_therapixbio.htm">Press Release issued by Therapix Biosciences Ltd. on October 10, 2019, titled &ldquo;Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.&rdquo;</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">1</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Therapix Biosciences Ltd.</U></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 10, 2019</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;Oz Adler<BR>
Title: Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">2</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f6k101019ex99-1_therapixbio.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY THERAPIX BIOSCIENCES LTD. ON OCTOBER 10, 2019, TITLED "THERAPIX BIOSCIENCES PROVIDES UPDATE ON PLANNED MERGER WITH DESTINY BIOSCIENCES GLOBAL CORP."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><B><BR>
<IMG SRC="image_001.jpg" ALT="" STYLE="height: 89px; width: 212px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><B>Therapix Biosciences Provides Update
on Planned Merger With Destiny Biosciences Global Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0">TEL AVIV, Israel, Oct. 10, 2019 /PRNewswire/ --<B>&nbsp;Therapix
Biosciences Ltd.</B>&nbsp;(&quot;Therapix&quot; or the &quot;Company&quot;) (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical
company focusing on the development of cannabinoid-based treatments, announced today an update on its planned merger with Destiny
Biosciences Global Corp. (&quot;Destiny&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">On July 23, 2019,&nbsp;Therapix announced the signing
of a Letter of Intent&nbsp;for a proposed merger with Destiny. If completed, the transaction will create a combined company that
focuses on Therapix's proprietary IP and related technology, and assets pertaining to all clinical stage pharmaceutical applications
and Destiny's genomics-based breeding techniques and development capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">The Company previously stated that it expects to execute
a definitive agreement pertaining to the merger during the third quarter of 2019. According to the Letter of Intent, the parties
agreed to allow until October 31, 2019 to complete the&nbsp;definitive agreement before abandoning the transaction. The Company's
Board of Directors is willing to provide Destiny with additional time to complete its due diligence process. In addition, Destiny
has retained an investment bank to carry out a relative valuation analysis of both companies to assist the Destiny Board of Directors
in connection with the merger. Destiny informed the Company that the valuations are being completed, but initial draft results
of the valuations support the transaction and the relative pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><B>About Therapix Biosciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio
of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following
drug development programs based on tetrahydrocannabinol (THC): THX-110 for the treatment of Tourette syndrome (TS), for the treatment
of obstructive sleep apnea (OSA), and for the treatment of pain; and THX-160 for the treatment of pain. Please visit our website
for more information at www.therapixbio.com, the content of which is not part of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><B>Forward-looking statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">This press release contains forward-looking statements
within the meaning of the &quot;safe harbor&quot; provisions of the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. For example, the Company is using forward-looking statements when it discusses executing a definitive
merger agreement on or before October 31, 2019, that valuations support the transaction and the relative pricing, and completing
a transaction with Destiny. A definitive merger agreement may or may not be executed on or before October 31, 2019 and, if executed,
the merger will be subject to conditions before it can be completed. In addition, historic results of scientific research and clinical
and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar
conclusions. Because such statements deal with future events and are based on the Company's current expectations, they are subject
to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from
those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this
press release are subject to other risks and uncertainties, including those discussed under the heading &quot;Risk Factors&quot;
the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on May 15, 2019 and in subsequent
filings with the SEC. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise
any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future
events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><B>Investor Contact<BR>
</B><FONT STYLE="color: blue"><U>IR@therapixbio.com</U></FONT><BR>
Tel: +972-3-6167055<BR>
<FONT STYLE="color: blue"><U>info@therapixbio.com</U></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0&^4&AO=&]S:&]P(#,N,  X0DE-! 0
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M,#4P,QP";@ 45&AE<F%P:7@@0FEO<V-I96YC97,< F<  !P">@ "0TX< B@
M#%-E92!296QE87-E(!P"%  @4%).07)C:&EV95\Q665A<GQ796)S:71E1&ES
M=')I8G4< @\  !P"   "  0 _]L 0P $ @,# P($ P,#! 0$! 4)!@4%!04+
M" @&"0T+#0T-"PP,#A 4$0X/$P\,#!(8$A,5%A<7%PX1&1L9%AH4%A<6_]L
M0P$$! 0%!04*!@8*%@\,#Q86%A86%A86%A86%A86%A86%A86%A86%A86%A86
M%A86%A86%A86%A86%A86%A86%A86_\  $0@ JP&0 P$B  (1 0,1 ?_$ !T
M 0 " @,! 0             &" <) P0% @'_Q !:$  ! P," @,'# H0!00#
M   !  (#! 4&!Q$2(0@Q00D3(E%A<=(4%1<R-U9R=8&1E;,6,S9"8G24H;'1
M&",D-#A24U15@I*3HK*TPB5#5W/3)T1%@T9CP__$ !L! 0 " P$!
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M-VN-X9QC[JJ7<]898=-,[$T,D9,D>P>PMW_<[_&JDL^UM^"%M4R< 8Y7\O\
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M._\ J"^GTK(+521QOT)('>X_SR7RZJ?/=*N21FN 3W-'\\U)^Y_ZFUEDSUF
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MP+@=AN=]E8C[ ,#]Y.._1,'HKUUNTT=+4/A,6=WGE>.AV9DJJ9DXE WN6%K
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MFMS9&'9P$W%L?.-PN;)++3TF$WFEQZWT]'45%%*&-I86QE[^ @>U Y]@6/\
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M#X?=2TF&AJ(#*?$#&TC_ "+L:I:3W2[Y!55N-U]/2TUVX3<*>9SFM+P=^,
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7(B(B(B(B(B(B(B(B(B(B(B(B(B(O_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
